TORONTO, Jan. 3, 2018 /CNW/ -- Ehave, Inc. (OTCQB: EHVVF), a healthcare company dedicated to empowering the mental health community with next-generation digital solutions, today announced that the Company has created a baseline concussion assessment tool that is now available on Ehave Connect, a digital "App Store" designed to enhance access to a broad array of content offered by Ehave and its growing roster of mental healthcare partners. The test will record baseline concussion symptoms using validated cognitive assessments and, via the robust Ehave Core Platform, provide extensive information about the athlete's history with concussions upon repeat assessment following acute injury. The platform can also be used to track treatment progress to help guide return-to-sport and return-to-school strategies.
As many as 1.6-3.8 million sports-related concussions occur in the U.S. each year and it is estimated that up to 50% of concussions go unreported. Factors contributing to the underreporting of concussive injury include gaps in knowledge concerning concussion symptoms, beliefs that the injury is not serious, and unwillingness to be removed from competition. Despite this underreporting, concussion incidence rates have been increasing in the past two decades.
Baseline concussion tests are an important piece in concussion management, and an area that is uniquely suited to the benefits of Ehave's mental health platform. Baseline assessments are typically taken as a preventative measure prior to a sport season. The same test can be taken again by the athlete/caregiver after an injury to provide comparative pre- and post-injury scores. Comparing post-injury test scores of an individual to their own baseline test scores as opposed to the general population is considered best practice.
Prateek Dwivedi, CEO of Ehave, said, "Mild traumatic brain injury (mTBI), or concussion, is the most common type of traumatic brain injury and is part of the target group of mental and cognitive conditions that Ehave is currently focused on. Initially, we plan to focus marketing of our baseline concussion test on school boards and amateur sports leagues where the need is greatest. Separately, Ehave is currently exploring Ehave Connect to manage treatment plans and track patient outcomes as part of a clinical trial to evaluate medical cannabis's potential ability to provide relief to persons suffering from post-traumatic stress disorder ("PTSD"). This use of our platform may be extended to mTBI, where early research has indicated the potential utility of cannabinoids in the treatment of both acute and chronic traumatic brain injury."
About Ehave, Inc.
Ehave is empowering the mental healthcare community with a next-generation of data-rich tools designed to improve patient management, diagnosis and treatment. With Ehave Connect, Ehave's mental health informatics platform, clinicians can make objective, data-driven decisions while keeping patients informed and engaged throughout their mental healthcare journey. Ehave Connect offers a powerful set of core features that integrate with a growing selection of tools and applications developed by Ehave and its leading partners, including Multi-Health Systems ("MHS"), a leading publisher of psychological assessments. Ehave is initially focused on improving the standard of care in attention deficit hyperactivity disorder ("ADHD"), through its collaboration with the Hospital for Sick Children ("SickKids"). Ehave Connect is also being utilized to advance the validation and optimization of medical cannabis, through its collaboration with MedReleaf. For more information, visit https://www.ehave.com/.
Forward-Looking Statement Disclaimer
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements: (i) the initiation, timing, progress and results of the Company's research, manufacturing and other development efforts; (ii) the Company's ability to advance its products to successfully complete development and commercialization; (iii) the manufacturing, development, commercialization, and market acceptance of the Company's products; (iv) the lack of sufficient funding to finance the product development and business operations; (v) competitive companies and technologies within the Company's industry and introduction of competing products; (vi) the Company's ability to establish and maintain corporate collaborations; (vii) loss of key management personnel; (viii) the scope of protection the Company is able to establish and maintain for intellectual property rights covering its products and its ability to operate its business without infringing the intellectual property rights of others; (ix) potential failure to comply with applicable health information privacy and security laws and other state and federal privacy and security laws; and (x) the difficulty of predicting actions of the USA FDA and its regulations. All forward-looking statements included in this press release are made only as of the date of this press release. The Company assumes no obligation to update any written or oral forward-looking statement unless required by law. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is contained under the heading "Risk Factors" in Ehave, Inc.'s Registration Statement on Form F-1 filed with the Securities and Exchange Commission (SEC) on September 24, 2015, as amended, which is available on the SEC's website, http://www.sec.gov.
Janine McCargo (Media)
SOURCE Ehave, Inc.